Cargando…
Long-term administration of Tolvaptan to patients with decompensated cirrhosis
Aim: Tolvaptan, an oral vasopressin-2 antagonist, sometimes improves hepatic edema including ascites in patients with decompensated cirrhosis. In this study, we examined the effectiveness and survival advantage in patients with the long-term administration of tolvaptan. Methods: A total of 115 patie...
Autores principales: | Kanayama, Kengo, Chiba, Tetsuhiro, Kobayashi, Kazufumi, Koroki, Keisuke, Maruta, Susumu, Kanzaki, Hiroaki, Kusakabe, Yuko, Saito, Tomoko, Kiyono, Soichiro, Nakamura, Masato, Ogasawara, Sadahisa, Suzuki, Eiichiro, Ooka, Yoshihiko, Nakamoto, Shingo, Yasui, Shin, Kanda, Tatsuo, Maruyama, Hitoshi, Kato, Jun, Kato, Naoya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163362/ https://www.ncbi.nlm.nih.gov/pubmed/32308540 http://dx.doi.org/10.7150/ijms.41454 |
Ejemplares similares
-
Impact of acute decompensation on the prognosis of patients with hepatocellular carcinoma
por: Kondo, Takayuki, et al.
Publicado: (2022) -
Switching to systemic therapy after locoregional treatment failure: Definition and best timing
por: Ogasawara, Sadahisa, et al.
Publicado: (2020) -
Left gastric vein-based noninvasive test for esophageal varices: a same-day comparison of portal hemodynamic assessment with endoscopic appearance
por: Maruyama, Hitoshi, et al.
Publicado: (2018) -
Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma
por: Maeda, Takahiro, et al.
Publicado: (2019) -
The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma
por: Kanzaki, Hiroaki, et al.
Publicado: (2021)